###begin article-title 0
###xml 60 64 <span type="species:ncbi:10090">mice</span>
GRK5 deficiency exaggerates inflammatory changes in TgAPPsw mice
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 196 205 196 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 260 264 <span type="species:ncbi:10090">mice</span>
###xml 735 739 <span type="species:ncbi:10090">mice</span>
Deficiency of membrane G-protein coupled receptor (GPCR) kinase-5 (GRK5) recently has been linked to early AD pathogenesis, and has been suggested to contribute to augmented microglial activation in vitro by sensitizing relevant GPCRs. However, GRK5 deficient mice did not show any signs of microgliosis, except for their moderate increase in axonal defects and synaptic degenerative changes during aging. We have speculated that one possible reason for the absence of microgliosis in these animals might be due to lack of an active inflammatory process involving activated GPCR signaling, since GRKs only act on activated GPCRs. The objective of this study was to determine whether the microgliosis is exaggerated in TgAPPsw (Tg2576) mice also deficient in GRK5, in which fibrillar beta-amyloid (Abeta) and an active inflammatory process involving activated GPCR signaling are present.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
Both quantitative and qualitative immunochemistry methods were used to evaluate the microgliosis and astrogliosis in these animals.
###end p 5
###begin title 6

###end title 6
###begin title 7
Results
###end title 7
###begin p 8
###xml 71 75 <span type="species:ncbi:10090">mice</span>
We found that inactivation of one copy of the GRK5 gene in the TgAPPsw mice resulted in approximately doubled extent of microgliosis, along with significantly exaggerated astrogliosis, in both hippocampus and cortex of the aged animals. Consistent with previous observations, the activated microglia were located primarily near or surrounding the fibrillar Abeta deposits.
###end p 8
###begin title 9
Conclusion
###end title 9
###begin p 10
###xml 45 53 45 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 254 258 <span type="species:ncbi:10090">mice</span>
The results demonstrate that GRK5 deficiency in vivo significantly exaggerates microgliosis and astrogliosis in the presence of an inflammatory initiator, such as the excess fibrillar Abeta and the subsequent active inflammatory reactions in the TgAPPsw mice.
###end p 10
###begin title 11
Background
###end title 11
###begin p 12
###xml 448 449 448 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 450 451 450 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
Alzheimer's disease (AD) is a devastating neurodegenerative disorder affecting a growing number among the aging population. Although its etiology remains to be elucidated, pathological evidence indicates that, in addition to the characteristic senile plaques and neurofibrillary tangles, significant brain inflammatory changes, featured with exaggerated gliosis and increased proinflammatory cytokines, are an important component of the pathology [1,2].
###end p 12
###begin p 13
###xml 355 356 355 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
Inflammation is a double-edged sword. For instance in AD, an appropriate degree of inflammatory reaction may be beneficial for clearance of aggregated proteins and/or degenerated cells. However, if the inflammation is overly reactive, the secondary inflammatory neuronal damage may become a driving force for the disease, as appears to be the case in AD [1]. Therefore, it is important to understand what factors may exaggerate the brain inflammation in AD so that corresponding therapeutic approaches can be developed to ameliorate such changes.
###end p 13
###begin p 14
###xml 381 382 368 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 383 384 370 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 463 464 450 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 791 792 775 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 793 794 777 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1010 1011 994 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1049 1050 1033 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1051 1052 1035 1036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
The extent of inflammatory reactions may be regulated by a variety of factors, such as proinflammatory cytokines, chemokines, complement systems, and others. In AD, fibrillar beta-amyloid (Abeta) has been shown to directly activate microglial cells and result in increased levels of proinflammatory cytokines, such as interleukin-1 beta (IL-1beta) and tumor necrosis factor-alpha [1-3]. In addition, it can activate the complement system to generate C3a and C5a [4]. Moreover, fibrillar Abeta accumulation is associated with increased levels of many chemokines and chemokine receptors, such as monocyte chemoattractant protein-1 (CCR2 ligand), macrophage inflammatory protein 1 (CCR3 ligand), interferon-inducible protein-10 (CXCR3 ligand), IL-8 (ligand for CXCXR1 and CXCR2) and CCR1/3/5. [5-7]. Amongst the inflammatory regulators associated with AD, there is one large category that exerts their cellular effects through heterotrimeric G-protein-coupled receptors (GPCRs). These include all the chemokines [6] and the anaphylatoxins C3a and C5a [8,9].
###end p 14
###begin p 15
###xml 173 182 173 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 482 484 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 485 487 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 694 696 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 769 776 769 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1041 1043 1041 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1059 1067 1059 1067 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1117 1126 1117 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1217 1219 1217 1219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1220 1222 1220 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1590 1592 1584 1586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 821 825 <span type="species:ncbi:10090">mice</span>
###xml 1584 1588 <span type="species:ncbi:10090">mice</span>
In a recent study, we showed that deficiency of membrane GPCR kinase-5 (GRK5) occurs during early AD, and the GRK5 deficiency contributes to augmented microglial activation in vitro via impaired sensitization of relevant GPCRs [10]. GRK5 is one of seven GRK family members, whose primary function is to desensitize activated GPCRs by phosphorylating the activated receptor to promote uncoupling of receptor-dependent G-protein activation and by initiating receptor internalization [11,12]. Therefore, the lack of membrane (functional) GRK5 resulted in prolonged signaling and enhanced microglial activation, which well explained the phenomena that we observed in the cultured microglial cells [10]. Moreover, we speculated that the same phenomena might also take place in vivo. However, our later study in GRK5 deficient mice (GRK5KO), an animal model resembling the functional GRK5 deficiency in AD, failed to show any sign of microgliosis, except for moderate increase in axonal defects and synaptic degenerative changes in these animals [13]. The negative in vivo data appeared to be inconsistent with our earlier in vitro data. Nonetheless, a hallmark of GRK action is to function only after GPCRs are activated [11,12]. In other words, whether or not an impact of GRK5 deficiency on a particular stimulus can be revealed depends on whether or not such a stimulus is present. We have reported that, although the GRK5 deficiency indeed caused a mild increase of Abeta level, no fibrillar Abeta deposits or any significant signs of microglial activation were observed in the GRK5KO mice [13]. Therefore, we speculated that one reason for the absence of microgliosis in these animals might be due to lack of inflammatory initiators, such as fibrillar Abeta, or any of the downstream chemokines or anaphylatoxins.
###end p 15
###begin p 16
###xml 274 276 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 277 279 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 39 43 <span type="species:ncbi:10090">mice</span>
###xml 66 70 <span type="species:ncbi:10090">mice</span>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
###xml 97 102 <span type="species:ncbi:9606">human</span>
###xml 315 319 <span type="species:ncbi:10090">mice</span>
In this study, we crossbred the GRK5KO mice with TgAPPsw (Tg2576) mice. TgAPPsw mice overexpress human beta-amyloid precursor protein (betaAPP) carrying Swedish double mutations, and have been shown to display fibrillar Abeta deposition and moderate levels of inflammation [14-16]. Therefore, the resultant TgAPPsw mice deficient in GRK5 should provide an ideal model to determine if our previous speculations are correct, and GRK5 deficiency plays a significant role in enhancing brain inflammation in AD.
###end p 16
###begin title 17
Methods
###end title 17
###begin title 18
Animals
###end title 18
###begin p 19
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 344 347 344 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 352 355 352 355 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 357 359 357 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 378 381 378 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 386 389 386 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 391 393 391 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 413 416 413 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 421 424 421 424 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 426 428 426 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 455 458 455 458 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 463 466 463 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 468 470 468 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 528 530 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 531 533 531 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 7 11 <span type="species:ncbi:10090">mice</span>
###xml 217 221 <span type="species:ncbi:10090">mice</span>
###xml 275 279 <span type="species:ncbi:10090">mice</span>
###xml 475 479 <span type="species:ncbi:10090">mice</span>
###xml 574 578 <span type="species:ncbi:10090">mice</span>
GRK5KO mice were generated by targeted deletion of exons 7 and 8 of the GRK5 gene, encoding critical sub-elements I through III of the protein kinase catalytic domain, as detailed previously [17]. Heterozygous GRK5KO mice (C57/BL6 background) were bred with TgAPPsw (Tg2576) mice (also with a C57/BL6 background) to produce wild type (WT, APPsw-/-/GRK5+/+, n = 6), GRK5KO (APPsw-/-/GRK5+/-, n = 6), TgAPPsw (APPsw+/-/GRK5+/+, n = 6), and the double (APPsw+/-/GRK5+/-, n = 6) mice for this study. Due to known gender difference [18-20] [Li, 2008, BRB-submitted], only female mice (18-month old) were used in this study. A tail DNA preparation was used for genotyping as described below. All procedures for using these animals were approved by the KCVAMC Institutional Animal Care and Use Committee.
###end p 19
###begin title 20
Genotyping
###end title 20
###begin p 21
###xml 53 55 53 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 774 775 772 773 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1166 1167 1138 1139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 198 203 <span type="species:ncbi:9606">human</span>
###xml 360 365 <span type="species:ncbi:9606">human</span>
###xml 422 428 <span type="species:ncbi:10090">murine</span>
###xml 624 630 <span type="species:ncbi:10090">murine</span>
Mouse-tail DNA was prepared as previously described [13]. Genotyping was performed by polymerase chain reaction (PCR) amplification of the tail genomic DNA with five different primers together: two human APP-specific primers, 5'CGGAGGAGGATGACTCGGAT3' and 5'CAGCTGCTGTCTCTCGTTGG3', which amplify a 500 bp DNA fragment, were used to identify the presence of the human APP transgene; three additional primers specific for WT murine GRK5 (425 bp) and the GRK5KO loci (200 bp) (5'CAAGTGTGAGGTAGGGTACAGAAT3', 5'CTATCCATTCACCTCCATGCTCCC3', and 5'AACTCTGGTACAGACAGGATCTCT3') were used to identify the presence of WT or the targeted murine GRK5 gene. The PCR used a 20 mul reaction volume containing 1.25 units of Flexi DNA polymerase (Promega, Madison, WI), 200 muM dNTPs, 2 mM MgCl2, and 250 nM of each of the APP preimers and 1 muM of each of the three GRK5 primers. The amplification protocol entailed 35 cycles of denaturation at 94degreesC for 15 s, annealing at 62degreesC for 15 s and extension at 72degreesC for 15 s, and then followed by a 10-min final extension at 72degreesC. The PCR products (10 mul) were then analyzed and visualized on 1.5% agarose gels. Fig. 1 shows an example of a typical genotyping result including the four different genotypes used in this study.
###end p 21
###begin p 22
###xml 0 63 0 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Genotypes and GRK5 expression in TgAPPsw mice with reduced GRK5</bold>
###xml 130 133 130 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 138 141 138 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 170 173 170 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 178 181 178 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 198 201 198 201 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 206 209 206 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 238 241 238 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 246 249 246 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 41 45 <span type="species:ncbi:10090">mice</span>
###xml 227 231 <span type="species:ncbi:10090">mice</span>
###xml 309 314 <span type="species:ncbi:9606">human</span>
Genotypes and GRK5 expression in TgAPPsw mice with reduced GRK5. Top panel, an example of the genotyping results for the WT (APPsw-/-/GRK5+/+), heterozygote GRK5KO (APPsw-/-/GRK5+/-), TgAPPsw (APPsw+/-/GRK5+/+), and the double mice (APPsw+/-/GRK5+/-) using the ascribed five primers. 500 base pair (bp) band, human APPsw; 425 bp band, WT GRK5; 200 bp band, inactivated GRK5. Bottom panels are representative Western blots for GRK5 and beta-actin (internal control for the amounts of sample loaded), respectively, as indicated.
###end p 22
###begin title 23
Tissue preparations
###end title 23
###begin p 24
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 542 546 <span type="species:ncbi:10090">mice</span>
All animals were anesthetized and perfused with cold phosphate buffered saline (PBS), their brains removed, and left hemispheres were post-fixed with 4% paraformaldehyde and processed for pathology. To minimize experimental variations, multi-brain embedding and sectioning techniques were adapted according to previously published procedures [13]. Briefly, twenty-four left hemispheres (including six from each genotype) were embedded into six blocks, with each block containing one hemisphere from each of the WT, GRK5KO, APP and the double mice, respectively. The multi-brain embedding allows the subsequent sectioning and staining procedures for all samples in a single block to be performed in a unified condition, which reduces variations that often occur when each brain is manipulated separately. Frozen sections were taken at a thickness of 20 mum in the coronal plane through the hemispheres. All sections were collected sequentially into eight groups with 160 mum intervals.
###end p 24
###begin title 25
Immunofluorescent (IF) staining
###end title 25
###begin p 26
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 134 139 <span type="species:ncbi:10090">mouse</span>
###xml 169 174 <span type="species:ncbi:9606">human</span>
###xml 240 243 <span type="species:ncbi:10116">rat</span>
###xml 312 315 <span type="species:ncbi:10116">rat</span>
###xml 323 328 <span type="species:ncbi:10090">mouse</span>
###xml 389 394 <span type="species:ncbi:10090">mouse</span>
###xml 457 463 <span type="species:ncbi:9986">rabbit</span>
###xml 493 498 <span type="species:ncbi:9606">human</span>
###xml 655 661 <span type="species:ncbi:9986">rabbit</span>
IF staining was performed on the multi-brain sections as previously described [13]. The only difference was the target antibody used: mouse monoclonal antibody (mAb) to human Abeta (Alpha Diagnostics International, San Antonio, TX; 1:600), rat mAb to CD45 (MCA1388, Clone: IBL-3/16, Serotec, Raleigh, NC; 1:25), rat mAb to mouse CD11b (Mac-1, Clone: M1/70.15, Serotec, Raleigh, NC; 1:25), mouse mAb to CD11b/c (Clone MRC OX-42, Serotec, Raleigh, NC; 1:25), rabbit polyclonal antibody (pAb) to human IL-1beta (Santa Cruz Biotechnology, Santa Cruz, CA; 1:25), mAb to glial fibrillary acidic protein (GFAP) conjugated to Cy3 (Sigma, St. Louis, MO;1:200), or rabbit pAb to IL-6 (Pierce Biotechnology, Rockford, IL; 1:100). DAPI (Invitrogen Corporation, Carlsbad, CA) was used to detect nuclei.
###end p 26
###begin title 27
Image Analysis
###end title 27
###begin p 28
###xml 130 132 130 132 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 150 152 150 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1280 1281 1279 1280 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
For quantitative image analysis, serial coronal sections taken from 1.70 to 3.16 mm posterior to the bregma were examined for CD45+ microglia and GFAP+ astrocytes. Six animals from each group were evaluated. For each animal, antigens were detected in 5 parallel multi-brain sections having a defined distance of 160 mum and showing both the hippocampus and cortex. In each section, the hippocampus and the cortex were evaluated for the number of stained cells, and integral staining density (sum of all individual optical densities of each pixel in the area being measured). Images were acquired as digitized tiff files to retain maximal resolution using a Leica DMI 6000 B microscope microscope at 100 x final magnification with an attached digital camera system (Leica DFC 340 FX, Heerbrugg, Germany). The digital images were then routed into a Windows PC for quantitative analyses using Image-Pro Plus software, with the examiner blinded to sample identifiers. To maintain consistency across animals, a rectangular box (0.42 x 0.26 mm) was centered over the area of interest. Except for fewer sections used, all other quantifying procedures were the same as stereological quantification. The final results were shown as number of immunopositive cells or immunoreactivity per mm2.
###end p 28
###begin title 29
Western blot
###end title 29
###begin p 30
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 354 360 <span type="species:ncbi:9986">rabbit</span>
At euthanasia, the cold PBS-perfused right hemispheres were further dissected into anterior cortex, posterior cortex, striatum, hippocampus, brainstem, and cerebellum. Protein extract preparation, total protein content determination, western blotting, and semi-quantitative analyses were performed as previously described [10,13]. Primary Abs used were: rabbit pAb to GRK5 (Santa Cruz Biotechnology, Santa Cruz, CA; 1:200) and mAb to beta-actin (Sigma, St. Louis, MO; 1:1000).
###end p 30
###begin title 31
Statistics
###end title 31
###begin p 32
Data were expressed as the mean +/- S.E.M, and analyzed by ANOVA using Prism 4.3 (GraphPad Software, San Diego, CA). Post-hoc comparisons of means were made using Bonferroni's method with significance set at 0.05.
###end p 32
###begin title 33
Results
###end title 33
###begin p 34
###xml 288 291 288 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 296 299 296 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 336 339 336 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 344 347 344 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 364 367 364 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 372 375 372 375 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 398 401 398 401 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 406 409 406 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 434 435 434 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 114 118 <span type="species:ncbi:10090">mice</span>
###xml 135 139 <span type="species:ncbi:10090">mice</span>
###xml 166 170 <span type="species:ncbi:10090">mice</span>
###xml 411 415 <span type="species:ncbi:10090">mice</span>
###xml 606 610 <span type="species:ncbi:10090">mice</span>
In order to determine whether GRK5 deficiency has an impact on brain inflammation in AD, we crossbred the TgAPPsw mice with the GRK5KO mice and generated the TgAPPsw mice deficient in GRK5. Only heterozygotes were used in this study, which included four genotype groups: WT control (APPsw-/-/GRK5+/+), GRK5KO heterozygote control (APPsw-/-/GRK5+/-), TgAPPsw (APPsw+/-/GRK5+/+) and the double (APPsw+/-/GRK5+/-) mice. As shown in Fig. 1, inactivation of one copy of the GRK5 gene resulted in at least 50% down-regulation of the GRK5 expression at the protein level in the heterozygote GRK5KO and the double mice.
###end p 34
###begin p 35
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 477 481 477 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A&#8211;D</xref>
###xml 502 506 502 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2E&#8211;H</xref>
###xml 662 664 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 671 673 671 673 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 752 756 749 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A&#8211;C</xref>
###xml 860 862 857 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 863 865 860 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 929 933 926 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3D&#8211;F</xref>
###xml 1060 1062 1057 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3G</xref>
###xml 1472 1473 1463 1464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1636 1638 1621 1623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3H</xref>
###xml 1669 1671 1654 1656 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1694 1696 1679 1681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3I</xref>
###xml 91 95 <span type="species:ncbi:10090">mice</span>
###xml 137 141 <span type="species:ncbi:10090">mice</span>
###xml 528 532 <span type="species:ncbi:10090">mice</span>
###xml 560 564 <span type="species:ncbi:10090">mice</span>
###xml 775 778 <span type="species:ncbi:10116">rat</span>
###xml 951 956 <span type="species:ncbi:10090">mouse</span>
###xml 1741 1745 <span type="species:ncbi:10090">mice</span>
Evaluation of potential changes in brain inflammation was performed in 18-month old female mice, due to the known gender impact in these mice [18-20] [Li, 2008, BRB-submitted]. Immunofluorescent staining with antibodies against microglial and astrocyte markers was employed to reveal changes in microgliosis and astrogliosis. Our initial examination with antibody against CD45, a surface marker of microglia [15], revealed an increase of microgliosis in both hippocampal (Fig. 2A-D) and cortical (Fig. 2E-H) areas of the double mice as compared to the TgAPPsw mice. Subsequent characterization of the microgliosis showed that, consistent with previous findings [15], CD45+ microglial cells were largely located surrounding or near Abeta deposits (Fig. 3A-C). Staining with a rat mAb to CD11b (Mac-1), another well-established microglial and macrophage marker [15,21], revealed similar changes of microglia in these animals (Fig. 3D-F). In addition, a mouse mAb OX-42 to CD11b/c also decorated the activated microglial cells in a way similar to anti-CD45 (Fig. 3G). However, at least in our experiments, OX-42 appeared to non-specifically stain the Abeta plaques, in addition to its positive staining for microglial cells. It has been previously established that activated microglial cells, at least at the early phase, produce IL-1beta, an important proinflammatory cytokine that participates in a self-sustained vicious cycle to amplify the inflammatory neuronal damage [2]. Our examination revealed that, although less profound than CD45 immunoreactivity (IR), IL-1beta-IR was indeed found near or surrounding the Abeta plaques (Fig. 3H) and was colocalized with CD45+ microglial cells (Fig. 3I). Therefore, the microgliosis in the double mice displayed similar traits to that observed in other AD transgenic models, except for the exaggerated extent.
###end p 35
###begin p 36
###xml 14 16 14 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 96 0 96 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Increased CD45<sup>+ </sup>microglial cells in hippocampus and cortex of the TgAPPsw mice with reduced GRK5</bold>
###xml 171 177 171 177 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A-D) </bold>
###xml 188 194 188 194 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(F-I) </bold>
###xml 201 203 201 203 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A </bold>
###xml 204 205 204 205 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 229 231 229 231 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B </bold>
###xml 232 233 232 233 <bold xmlns:xlink="http://www.w3.org/1999/xlink">G</bold>
###xml 245 247 245 247 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C </bold>
###xml 248 249 248 249 <bold xmlns:xlink="http://www.w3.org/1999/xlink">H</bold>
###xml 273 275 273 275 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D </bold>
###xml 276 277 276 277 <bold xmlns:xlink="http://www.w3.org/1999/xlink">I</bold>
###xml 313 315 313 315 <bold xmlns:xlink="http://www.w3.org/1999/xlink">I </bold>
###xml 329 333 329 333 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A-D </bold>
###xml 337 340 337 340 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F-I</bold>
###xml 358 360 357 359 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E </bold>
###xml 361 362 360 361 <bold xmlns:xlink="http://www.w3.org/1999/xlink">J</bold>
###xml 408 409 407 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 443 444 442 443 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E</bold>
###xml 458 459 457 458 <bold xmlns:xlink="http://www.w3.org/1999/xlink">J</bold>
###xml 553 555 552 554 <bold xmlns:xlink="http://www.w3.org/1999/xlink">J </bold>
###xml 569 571 568 570 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E </bold>
###xml 572 573 571 572 <bold xmlns:xlink="http://www.w3.org/1999/xlink">J</bold>
###xml 74 78 <span type="species:ncbi:10090">mice</span>
###xml 267 271 <span type="species:ncbi:10090">mice</span>
###xml 475 479 <span type="species:ncbi:10090">mice</span>
Increased CD45+ microglial cells in hippocampus and cortex of the TgAPPsw mice with reduced GRK5. Representative IF results with anti-CD45 staining (green) in hippocampus (A-D) and cortex (F-I) of WT (A &F), heterozygote GRK5KO (B &G), TgAPPsw (C &H), and the double mice (D &I), respectively. Scale bar in panel I is for panels A-D and F-I: 100 mum. Panels E &J, examples of high magnification views of CD45+-microglial cells in hippocampus (E) and cortex (J) of the double mice that show details of activated microglial morphology. Scale bar in panel J is for panels E &J: 20 mum. Blue indicates reference DAPI staining of nuclei.
###end p 36
###begin p 37
###xml 0 131 0 125 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Colocalization of activated microglial cells with A&#946; plaques and IL-1&#946; immunoreactivity in the TgAPPsw mice with reduced GRK5</bold>
###xml 140 143 134 137 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A-C</bold>
###xml 165 167 156 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 176 177 167 168 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 204 206 195 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 224 225 215 216 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 265 266 256 257 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 317 318 307 308 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 319 320 309 310 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 329 332 319 322 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D-F</bold>
###xml 354 356 341 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 365 366 352 353 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 394 396 381 383 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 414 415 401 402 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E</bold>
###xml 455 456 442 443 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 507 508 493 494 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 509 510 495 496 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 518 519 504 505 <bold xmlns:xlink="http://www.w3.org/1999/xlink">G</bold>
###xml 940 941 925 926 <bold xmlns:xlink="http://www.w3.org/1999/xlink">H</bold>
###xml 978 980 960 962 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1089 1090 1067 1068 <bold xmlns:xlink="http://www.w3.org/1999/xlink">I</bold>
###xml 1114 1116 1092 1094 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
###xml 282 286 <span type="species:ncbi:10090">mice</span>
###xml 472 476 <span type="species:ncbi:10090">mice</span>
###xml 1058 1062 <span type="species:ncbi:10090">mice</span>
###xml 1192 1196 <span type="species:ncbi:10090">mice</span>
Colocalization of activated microglial cells with Abeta plaques and IL-1beta immunoreactivity in the TgAPPsw mice with reduced GRK5. Panels A-C, IF staining of Abeta+ plaques (A, red) and surrounding CD45+ microglial cells (B, green), as well as their merged view (C) in the double mice. Scale bar: 50 mum for panels A-C. Panels D-F, IF staining of Abeta+ plaques (D, red) and surrounding CD11b+ microglial cells (E, green), as well as their merged view (F) in the double mice. Scale bar: 50 mum for panels D-F. Panel G, an example of merged view for CD45 (green) and CD11b/c (clone OX42, red) co-staining of the microglial cells. The image showed that, at least in this particular experimental paradigm, the CD45 antibody stained more specifically for the microglial cell profiles; while the OX42 antibody, in addition to its positive staining of the microglial cells, also non-specifically decorated the plaques. Scale bar: 45 mum. Panel H, an example of merged view for Abeta+ plaques (red) and surrounding IL-1beta immunoreactivity (green) in the double mice. Scale bar: 30 mum. Panel I, colocalization of CD45+ microglial cells (green) with IL-1beta immunoreactivity (red) in the double mice. Scale bar: 30 mum. Blue indicates reference DAPI staining of nuclei.
###end p 37
###begin p 38
###xml 100 102 100 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 125 127 125 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 311 313 311 313 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 483 485 483 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 647 649 647 649 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 802 804 802 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 235 239 <span type="species:ncbi:10090">mice</span>
###xml 273 277 <span type="species:ncbi:10090">mice</span>
###xml 418 422 <span type="species:ncbi:10090">mice</span>
###xml 435 439 <span type="species:ncbi:10090">mice</span>
###xml 584 588 <span type="species:ncbi:10090">mice</span>
###xml 796 800 <span type="species:ncbi:10090">mice</span>
###xml 914 919 <span type="species:ncbi:9606">human</span>
###xml 962 968 <span type="species:ncbi:10090">murine</span>
###xml 1094 1098 <span type="species:ncbi:10090">mice</span>
###xml 1236 1240 <span type="species:ncbi:10090">mice</span>
###xml 1452 1456 <span type="species:ncbi:10090">mice</span>
To better understand the extent of the exaggerated microgliosis in these animals, we quantified CD45+ microglial cells per mm2 in hippocampus and cortex. Our quantitative image analysis (Fig. 4A &4B) showed that, as compared to the WT mice, both the TgAPPsw and the double mice displayed significantly more CD45+ microglial cells in both of the examined brain regions (p < 0.001 for all); when compared to the TgAPPsw mice, the double mice had approximately double the number of CD45+ microglial cells, in both hippocampus and cortex (P < 0.001). In addition, the heterozygote GRK5KO mice did not show any significant changes in the number of CD45+ microglial cells, as compared to the WT, which is consistent with our previous report for the negative finding of brain inflammation in the GRK5KO mice [13]. When two-way ANOVA was used to analyze interactions between the two gene modifications (over-expression of human APPsw and inactivation of one copy of the murine GRK5 gene), a significance of p < 0.001 was revealed. Meanwhile, the changes caused by both gene modifications in the double mice were significantly higher than the sum of the changes caused by APPsw over-expression in TgAPPsw and by GRK5 gene inactivation in GRK5KO mice (p = 0.003 for hippocampus and p < 0.001 for cortex). These results indicate that the two gene modifications synergistically interact with each other, and both contribute the microgliosis observed in the double mice.
###end p 38
###begin p 39
###xml 22 24 22 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 104 0 104 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Quantification of CD45<sup>+ </sup>microglial cells in hippocampus and cortex of the TgAPPsw mice with reduced GRK5</bold>
###xml 125 127 125 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 160 161 160 161 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 175 176 175 176 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 527 530 527 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 569 572 569 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 82 86 <span type="species:ncbi:10090">mice</span>
###xml 230 234 <span type="species:ncbi:10090">mice</span>
###xml 580 584 <span type="species:ncbi:10090">mice</span>
Quantification of CD45+ microglial cells in hippocampus and cortex of the TgAPPsw mice with reduced GRK5. The numbers of CD45+ microglial cells in hippocampus (A) and cortex (B) of WT, heterozygote GRK5KO, TgAPPsw, and the double mice were quantified as described in methods. Two way-ANOVAs revealed significant interactions between APPsw and GRK5 gene modifications for both hippocampus and cortex (P < 0.001 for both regions). The results for Bonferroni post-hoc comparisons of the means were shown as indicated. **P < 0.001 vs WT or heterozygote GRK5KO, ##P < 0.001 vs TgAPPsw mice.
###end p 39
###begin p 40
###xml 487 491 487 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A&#8211;H</xref>
###xml 650 654 647 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A&#8211;C</xref>
###xml 865 869 859 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6D&#8211;F</xref>
###xml 906 908 900 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7A</xref>
###xml 910 912 904 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7B</xref>
###xml 996 998 990 992 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1310 1312 1304 1306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1333 1335 1327 1329 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 321 325 <span type="species:ncbi:10090">mice</span>
###xml 353 357 <span type="species:ncbi:10090">mice</span>
###xml 379 383 <span type="species:ncbi:10090">mice</span>
###xml 400 404 <span type="species:ncbi:10090">mice</span>
###xml 476 480 <span type="species:ncbi:10090">mice</span>
###xml 553 557 <span type="species:ncbi:10090">mice</span>
###xml 961 965 <span type="species:ncbi:10090">mice</span>
###xml 1115 1119 <span type="species:ncbi:10090">mice</span>
###xml 1145 1149 <span type="species:ncbi:10090">mice</span>
###xml 1215 1219 <span type="species:ncbi:10090">mice</span>
###xml 1421 1425 <span type="species:ncbi:10090">mice</span>
In parallel to the microglial analysis, potential changes of astrogliosis in these animals were also assessed using IF staining with antibody to GFAP, an astrocyte-specific intermediate filament protein. We found more hypertrophic astrocytes brightly stained with anti-GFAP in both hippocampus and cortex from the double mice as compared to the TgAPPsw mice, and both the double mice and the TgAPPsw mice showed more hypertrophic astrocytes than the WT or heterozygous GRK5KO mice (Fig. 5A-H). Further characterization of the astrogliosis in the double mice revealed that although some of the hypertrophic astrocytes located near Abeta plaques (Fig. 6A-C), compared to the relation of microglia to Abeta plaques, hypertrophic astrocytes were more widespread in the entire brain region. In addition, at least some of the reactive astrocytes were IL-6 positive (Fig. 6D-F). Quantitative image analysis (Fig. 7A &7B) indicated that both the TgAPPsw and the double mice showed significantly more GFAP+ astrocytes in the hippocampus and cortex (p < 0.001 for all) as compared to either the WT or the heterozygous GRK5KO mice; furthermore, the double mice displayed greater numbers of astrocytes than that in the TgAPPsw mice (p < 0.01 for hippocampus and p < 0.001 for cortex). Consistent with our previous report [13], the number of GFAP+ astrocytes was not significantly different between the heterozygous GRK5KO and the WT mice. When two-way ANOVA was employed, significant interactions (p < 0.05 for hippocampus, and p < 0.01 for cortex) were revealed between the two gene modifications. The comparisons of effects of the double gene modifications with the sum of the effects of the each single gene modification alone revealed significant difference for the cortex (p = 0.02) but not for the hippocampus (p = 0.10).
###end p 40
###begin p 41
###xml 14 16 14 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 90 0 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Increased GFAP<sup>+ </sup>astrocytes in hippocampus and cortex of the TgAPPsw mice with reduced GRK5</bold>
###xml 165 171 165 171 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A-D) </bold>
###xml 182 188 182 188 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(E-H) </bold>
###xml 195 197 195 197 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A </bold>
###xml 198 199 198 199 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E</bold>
###xml 223 225 223 225 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B </bold>
###xml 226 227 226 227 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 239 241 239 241 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C </bold>
###xml 242 243 242 243 <bold xmlns:xlink="http://www.w3.org/1999/xlink">G</bold>
###xml 267 269 267 269 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D </bold>
###xml 270 271 270 271 <bold xmlns:xlink="http://www.w3.org/1999/xlink">H</bold>
###xml 68 72 <span type="species:ncbi:10090">mice</span>
###xml 261 265 <span type="species:ncbi:10090">mice</span>
Increased GFAP+ astrocytes in hippocampus and cortex of the TgAPPsw mice with reduced GRK5. Representative IF results with anti-GFAP staining (green) in hippocampus (A-D) and cortex (E-H) of WT (A &E), heterozygote GRK5KO (B &F), TgAPPsw (C &G), and the double mice (D &H), respectively. Blue indicates reference DAPI staining of nuclei. Scale bar: 100 mum.
###end p 41
###begin p 42
###xml 0 120 0 117 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Colocalization of reactive astrocytes with A&#946; plaques and IL-6 immunoreactivity in the TgAPPsw mice with reduced GRK5</bold>
###xml 154 156 148 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 165 166 159 160 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 188 190 182 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 211 212 205 206 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 252 253 246 247 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 304 305 297 298 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 306 307 299 300 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 316 319 309 312 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D-F</bold>
###xml 340 342 333 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 354 355 347 348 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 387 388 380 381 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E</bold>
###xml 428 429 421 422 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 480 481 472 473 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 482 483 474 475 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 98 102 <span type="species:ncbi:10090">mice</span>
###xml 269 273 <span type="species:ncbi:10090">mice</span>
###xml 445 449 <span type="species:ncbi:10090">mice</span>
Colocalization of reactive astrocytes with Abeta plaques and IL-6 immunoreactivity in the TgAPPsw mice with reduced GRK5. Panels A-C, IF staining of Abeta+ plaques (A, red) and nearby GFAP+ reactive astrocytes (B, green), as well as their merged view (C) in the double mice. Scale bar: 50 mum for panels A-C. Panels D-F, IF staining of GFAP+ astrocytes (D, red) and colocalized IL-6-IR (E, green), as well as their merged view (F) in the double mice. Scale bar: 20 mum for panels D-F. Blue indicates reference DAPI staining of nuclei.
###end p 42
###begin p 43
###xml 22 24 22 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 98 0 98 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Quantification of GFAP<sup>+ </sup>astrocytes in hippocampus and cortex of the TgAPPsw mice with reduced GRK5</bold>
###xml 124 126 124 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 138 140 138 140 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A </bold>
###xml 141 142 141 142 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 174 176 174 176 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C </bold>
###xml 177 178 177 178 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 196 198 196 198 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A </bold>
###xml 199 200 199 200 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 214 216 214 216 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B </bold>
###xml 217 218 217 218 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 460 461 460 461 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 487 488 487 488 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 490 491 490 491 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 497 498 497 498 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 598 601 598 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 638 641 638 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 76 80 <span type="species:ncbi:10090">mice</span>
###xml 272 276 <span type="species:ncbi:10090">mice</span>
###xml 649 653 <span type="species:ncbi:10090">mice</span>
Quantification of GFAP+ astrocytes in hippocampus and cortex of the TgAPPsw mice with reduced GRK5. Both the numbers of GFAP+ astrocytes (A &B) and the intensity of GFAP-IR (C &D) in hippocampus (A &C) and cortex (B &D) of WT, heterozygote GRK5KO, TgAPPsw, and the double mice were quantified as described in methods. Two way-ANOVAs revealed significant interactions between APPsw and GRK5 gene modifications with the interaction factors of p < 0.05 for panel A, and p < 0.01 for panels B, C, and D. The results for Bonferroni post-hoc comparisons of the means were shown as indicated. **P < 0.001 vs WT or GRK5KO; #P < 0.01, ##P < 0.001 vs TgAPPsw mice.
###end p 43
###begin p 44
###xml 197 199 197 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 373 375 373 375 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 511 513 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7C</xref>
###xml 515 517 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7D</xref>
###xml 1033 1037 <span type="species:ncbi:10090">mice</span>
It is known that both resting and reactive astrocytes express GFAP, but the latter usually expresses higher level of GFAP, and therefore stain brighter. Because of this, counting the number of GFAP+ astrocytes may not accurately reflect the extent of the astrogliosis. Therefore, a quantitative image analysis of GFAP-IR intensity was also performed in parallel to the GFAP+ cell counting. The results were similar to those from simple cell number counting, except that the significance was more striking (Fig. 7C &7D). The double gene modification effects were significantly higher than the sum of the each single gene alone for both hippocampus (p = 0.006) and cortex (p = 0.009). The interactions between the two gene modifications were also highly significant for both brain regions (p = 0.002 for hippocampus, and p = 0.005 for cortex). Therefore, these results suggest that Swedish mutated APP gene over-expression and GRK5 deficiency synergistically interact with each other to promote the astrogliosis observed in the double mice.
###end p 44
###begin title 45
Discussion
###end title 45
###begin p 46
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 898 900 898 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 901 903 901 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1498 1506 1495 1503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 60 64 <span type="species:ncbi:10090">mice</span>
###xml 138 142 <span type="species:ncbi:10090">mice</span>
###xml 394 398 <span type="species:ncbi:10090">mice</span>
###xml 920 924 <span type="species:ncbi:10090">mice</span>
###xml 1089 1093 <span type="species:ncbi:10090">mice</span>
By analyzing the extent of gliosis in the brains of TgAPPsw mice with normal or reduced GRK5 expression, we demonstrated that the TgAPPsw mice with reduced GRK5 displayed significantly exaggerated microgliosis and astrogliosis. Consistent with our previous report [13], GRK5 deficiency alone does not lead to any significant inflammatory changes in either the heterozygote or homozygote GRK5KO mice. However, when an inflammation is present, as evoked by overexpression of the Swedish mutated APP gene, the GRK5 deficiency synergistically interacts with the active inflammatory processes and leads to amplified inflammatory responses. Such phenomena are consistent with the manner of GRK action, as GRKs are not thought to induce signals directly, but rather, they primarily modify the activity of activated GPCRs by uncoupling the receptor from G-protein, and initialing receptor internalization [11,12]. In the GRK5KO mice, the reason why we did not observe a significant inflammation is likely because there was no an active inflammatory signaling for the GRK5 to act on. In the double mice, however, when Swedish mutated APP was overexpressed, the accumulation of fibrillar Abeta initiated a complex of active inflammatory processes, which provided an opportunity to reveal impact of GRK5 deficiency. As demonstrated in this study, inactivation of one copy of the native GRK5 gene led to approximately doubled extent of microgliosis and significantly exaggerated astrogliosis. Therefore, these in vivo results strongly support the model that GRK5 deficiency indeed plays a significant role in amplifying the brain inflammatory responses in AD, as we previously speculated.
###end p 46
###begin p 47
###xml 409 410 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 411 412 408 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 506 507 503 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 508 509 505 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 510 511 507 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 675 677 669 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 678 680 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 963 965 957 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 966 968 960 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1276 1278 1270 1272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1279 1281 1273 1275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1282 1284 1276 1278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1503 1511 1494 1502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1139 1143 <span type="species:ncbi:10090">mice</span>
###xml 1708 1712 <span type="species:ncbi:10090">mice</span>
Since the primary role of GRKs is to desensitize GPCRs and dampen the activated GPCRs signaling, deficiency of GRK5 may lead to hyperactivity of those GPCRs that are specifically regulated by GRK5. As previously demonstrated, the fibrillar Abeta can initiate a complicated inflammatory process, which may include increased levels of proinflammatory cytokines, chemokines, and activated complement components [1-7]. It is known that receptors for all chemokines and the anaphylatoxin C3a and C5a are GPCRs [6,8,9]. In fact, even fibrillar Abeta itself has been shown to activate GPCRs, such as macrophage scavenger receptor, or formyl chemotactic receptor 2 (FPR2 or FPRL-1) [22-24]. Therefore, theoretically, all these GPCRs could be potential substrates for GRK5. On the other hand, however, the substrate spectrums for different GRK members may overlap, and the lost function due to deficiency of one GRK member may be largely compensated by other GRK members [11,12]. Only when the lost function cannot be fully compensated, a phenotype relevant to the specific GPCR signaling can then be revealed. For example, GRK2, GRK5, and GRK6 KO mice have been shown to display selectively impaired desensitization of adrenergic, muscarinic and dopaminergic receptors, respectively [17,25,26]. Unfortunately, to the best of our knowledge, information regarding the specific regulation of GRK5 on most, if not all, of the GPCRs involved in the fibrillar Abeta initiated inflammatory processes, particularly the in vivo data, is unavailable. Therefore, further investigations are warranted to understand the detailed molecular mechanisms by which the GRK5 deficiency exaggerates the brain inflammation in the TgAPPsw mice.
###end p 47
###begin p 48
###xml 79 87 79 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 599 601 599 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 211 215 <span type="species:ncbi:10090">mice</span>
###xml 259 263 <span type="species:ncbi:10090">mice</span>
###xml 344 348 <span type="species:ncbi:10090">mice</span>
###xml 366 370 <span type="species:ncbi:10090">mice</span>
###xml 414 418 <span type="species:ncbi:10090">mice</span>
###xml 508 513 <span type="species:ncbi:10090">mouse</span>
###xml 544 548 <span type="species:ncbi:10090">mice</span>
###xml 580 585 <span type="species:ncbi:9606">human</span>
###xml 589 597 <span type="species:ncbi:9606">patients</span>
###xml 700 704 <span type="species:ncbi:10090">mice</span>
###xml 769 773 <span type="species:ncbi:10090">mice</span>
The main purpose of this study was to determine whether or not GRK5 deficiency in vivo contributes to exaggerate brain inflammation, and the results confirmed the positive role of GRK5 deficiency in the TgAPPsw mice. In the meantime, the fact that the double mice displayed significantly stronger inflammatory changes than those in the TgAPPsw mice makes the double mice a distinct model from the original TgAPPsw mice. It has been suggested that inflammatory responses in currently available APP transgenic mouse models, including the TgAPPsw mice, are not as strong as those in human AD patients [16]. Therefore, at least in resembling the strength of the inflammatory responses in AD, the TgAPPsw mice with reduced GRK5 may be a better model than the single TgAPPsw mice, and should serve as an additional AD animal model for relevant studies.
###end p 48
###begin title 49
Conclusion
###end title 49
###begin p 50
###xml 49 57 49 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 377 385 374 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 536 538 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 260 264 <span type="species:ncbi:10090">mice</span>
###xml 695 700 <span type="species:ncbi:10090">mouse</span>
###xml 772 777 <span type="species:ncbi:10090">mouse</span>
This study has demonstrated that GRK5 deficiency in vivo significantly exaggerates the microgliosis and astrogliosis in the presence of an inflammatory initiator, the excess fibrillar Abeta and the subsequent active brain inflammatory reactions in the TgAPPsw mice. In the absence of an active inflammatory response, however, the effects of the GRK5 deficiency on inflammation in vivo remain silent. These findings, along with our previous findings for the role of GRK5 deficiency in promoting axonal defects and synaptic degeneration [13] [Li, 2008, BRB-submitted], strongly support that the hypothesis that GRK5 deficiency plays a significant role in AD pathogenesis. In addition, the TgAPPsw mouse combined with deficient GRK5 is a better model than the single TgAPPsw mouse, due to a stronger resemblance to the strength of the inflammatory responses in AD.
###end p 50
###begin title 51
Abbreviations
###end title 51
###begin p 52
AD: Alzheimer's disease; Abeta: beta-amyloid; GPCRs: G-protein coupled receptors; GRK5: GPCR kinase-5; GRK5KO: GRK5 knockout; betaAPP: beta-amyloid precursor protein; PCR: polymerase chain reaction; PBS: phosphate buffered saline; IF: Immunofluorescent; mAb: monoclonal antibody; pAb: polyclonal antibody; GFAP: glial fibrillary acidic protein; IL-1beta: interleukin-1beta; IL-6: interleukin-6; IR, immunoreactivity.
###end p 52
###begin title 53
Competing interests
###end title 53
###begin p 54
The authors declare that they have no competing interests.
###end p 54
###begin title 55
Authors' contributions
###end title 55
###begin p 56
###xml 120 135 <span type="species:ncbi:10090">transgenic mice</span>
###xml 247 252 <span type="species:ncbi:10090">mouse</span>
LL carried out the pathological studies, performed the statistical analysis, and participated in the maintenance of the transgenic mice and initial drafting of the manuscript, JL participated in the establishment and maintenance of the transgenic mouse colonies, WZS designed the study, supervised and coordinated the experimental conduction, and helped to draft the manuscript. All authors read and approved the final manuscript.
###end p 56
###begin title 57
Acknowledgements
###end title 57
###begin p 58
###xml 365 370 <span type="species:ncbi:10090">mouse</span>
This study was supported by grants to WZS from the Medical Research and Development Service, Department of Veterans Affairs, the American Federation for Aging Research, and resources from the Midwest Biomedical Research Foundation. In addition, we sincerely thank Drs. Robert J. Lefkowitz and Richard T. Premont at Duke University for providing the original GRK5KO mouse breeding pairs, consultations and review of this manuscript.
###end p 58
###begin article-title 59
Inflammation in Alzheimer disease: driving force, bystander or beneficial response?
###end article-title 59
###begin article-title 60
Inflammation and neurodegenerative diseases
###end article-title 60
###begin article-title 61
Inflammation, autotoxicity and Alzheimer disease
###end article-title 61
###begin article-title 62
Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection
###end article-title 62
###begin article-title 63
###xml 73 78 <span type="species:ncbi:9606">human</span>
Amyloid-beta induces chemokine secretion and monocyte migration across a human blood--brain barrier model
###end article-title 63
###begin article-title 64
Chemokines and Alzheimer's disease
###end article-title 64
###begin article-title 65
CCR1 is an early and specific marker of Alzheimer's disease
###end article-title 65
###begin article-title 66
Monocyte chemoattractant protein-1-induced CCR2B receptor desensitization mediated by the G protein-coupled receptor kinase 2
###end article-title 66
###begin article-title 67
Ligand-induced phosphorylation of anaphylatoxin receptors C3aR and C5aR is mediated by "G protein-coupled receptor kinases
###end article-title 67
###begin article-title 68
Abnormality of G-protein-coupled receptor kinases at prodromal and early stages of Alzheimer's disease: an association with early beta-amyloid accumulation
###end article-title 68
###begin article-title 69
Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization
###end article-title 69
###begin article-title 70
G protein-coupled receptor kinases
###end article-title 70
###begin article-title 71
GRK5 deficiency leads to early Alzheimer-like pathology and working memory impairment
###end article-title 71
###begin article-title 72
###xml 48 63 <span type="species:ncbi:10090">transgenic mice</span>
Microglial response to amyloid plaques in APPsw transgenic mice [see comments]
###end article-title 72
###begin article-title 73
###xml 57 72 <span type="species:ncbi:10090">transgenic mice</span>
Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice
###end article-title 73
###begin article-title 74
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease
###end article-title 74
###begin article-title 75
###xml 115 119 <span type="species:ncbi:10090">mice</span>
Muscarinic supersensitivity and impaired receptor desensitization in G protein-coupled receptor kinase 5-deficient mice
###end article-title 75
###begin article-title 76
###xml 80 85 <span type="species:ncbi:10090">mouse</span>
Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease
###end article-title 76
###begin article-title 77
###xml 74 79 <span type="species:ncbi:9606">human</span>
###xml 99 114 <span type="species:ncbi:10090">transgenic mice</span>
Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice
###end article-title 77
###begin article-title 78
###xml 75 90 <span type="species:ncbi:10090">transgenic mice</span>
Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice
###end article-title 78
###begin article-title 79
Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system
###end article-title 79
###begin article-title 80
Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils
###end article-title 80
###begin article-title 81
Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1
###end article-title 81
###begin article-title 82
Beta amyloid peptide (Abeta42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages
###end article-title 82
###begin article-title 83
Essential role of beta-adrenergic receptor kinase 1 in cardiac development and function
###end article-title 83
###begin article-title 84
###xml 79 83 <span type="species:ncbi:10090">mice</span>
Dopaminergic supersensitivity in g protein-coupled receptor kinase 6-deficient mice
###end article-title 84

